Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2015

View Archived Issues

DS-107 cream as a promising new treatment for atopic dermatitis

LXRbeta partial agonist shows potential for the treatment of atherosclerosis

Researchers report CTNNB1 mutations in NMC and NMC-Fi for the first time

Ipsen and Hannover Medical School to research recombinant botulinum neurotoxins

Max Planck Society presents synthetic pneumococcal vaccines

DiscoveryBioMed receives NIH grant to discover adiponectin secretion stimulators

Investigators report presence of CD117 in Leydig cell tumors

Pharmakea divulges autotaxin inhibitors

Frizzled receptor antagonist attenuates adverse remodeling

Pfizer establishes grants program to advance PCSK9 research

Nurelin receives orphan drug designation in U.S.

Viral nanoparticle product AU-011 granted orphan drug status in U.S.

Actimmune receives FDA fast track designation for the treatment of Friedreich's ataxia

FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND

oxLDL-induced apoptotic dendritic cells show efficacy as a potential therapy for atherosclerosis

Celgene invests in Mesoblast and gains option to license cancer and inflammation cell therapies

ReNeuron files IND to begin U.S. phase I/II study candidate for retinitis pigmentosa

Medivir and Cancer Research Technology collaborate to develop ADAM8 inhibitors

Calitor Sciences discloses new PI3K inhibitors

Bristol-Myers Squibb patents RORgamma modulators

Vernalis presents PDK inhibitors

Eisai and Arena complete registrational studies of extended-release lorcaserin

Lilly Chk1 inhibitor granted U.S. orphan drug status for anal cancer

Merck & Co.'s grazoprevir/elbasvir gains BTDs from FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...